Enveric Biosciences Inc vs Howmet Aerospace Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Howmet Aerospace Inc trades at $225.24 (market cap $88.76B). The key difference: Howmet Aerospace Inc is far larger — about 13052.9× Enveric Biosciences Inc's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Howmet Aerospace Inc for 35 Days on average.
| ENVB | HWM | |
|---|---|---|
Market Cap | $6.80M | $88.76B |
Volume | 64,867 | 2,648,516 |
Sector | Health | Industrials |
52-Week High | $10.80 | $292.65 |
52-Week Low | $1.27 | $184.09 |
Typical Hold Time | 14 Days | 35 Days |
Enterprise Value | -$1.49M | $92.86B |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Howmet Aerospace (HWM) trades at $225.24, up 1.14% with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows bearish technical signals despite robust profitability metrics with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace strength and upcoming Q3 2026 earnings announcement on October 29, 2026.
Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 46% upside potential. Key risks include technical weakness, valuation multiples above industry averages, and dependence on aerospace sector recovery. The combination of strong fundamentals and analyst optimism suggests potential for recovery from current technical pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →